Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ketamin-tilføjelse til terapi til etableret status epilepticus behandlingsforsøg (KESETT) (KESETT)

11. november 2026 opdateret af: Jaideep Kapur, MD, University of Virginia

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

KESETT is a multicenter, randomized, blinded study to determine whether adding 1 mg/kg or 3 mg/kg dose of KET to 60 mg/kg LEV can terminate status epilepticus (SE) in a larger fraction of subjects with benzodiazepine-refractory SE than those treated with LEV (60 mg/kg) alone.

The primary outcome is termination of SE from 15 minutes after starting the study drug infusion, sustained until 60 minutes from enrollment without using additional anti-seizure medication. Termination of SE is determined by (1) improving consciousness and absence of clinically apparent seizures at 60 minutes or (2) absence of any electrographic SE after 15 minutes in those with EEG monitoring and no improvement in consciousness.

Secondary objectives include determining the relative safety of the treatment arms on defined safety outcomes and all adverse events, analysis of secondary/exploratory efficacy outcomes, and evaluation of both effectiveness and safety in the pediatric subpopulation.

The trial will initially allocate subjects equally (1:1:1) for the first 350 participants (burn-in period) before transitioning to response-adaptive randomization. Interim analyses will be conducted for efficacy and futility beginning when 350 subjects have been randomized, and will occur every 100 subjects thereafter. A maximum of 770 participants will be enrolled.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

770

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • Ikke rekrutterer endnu
        • UAB Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Lauren Walter, MD, MSPH
    • Arizona
      • Tucson, Arizona, Forenede Stater, 85724
        • Rekruttering
        • Banner University Medical Center - Tucson Campus
        • Kontakt:
        • Ledende efterforsker:
          • Aaron Leetch, MD
    • California
      • La Jolla, California, Forenede Stater, 92037
        • Ikke rekrutterer endnu
        • UC San Diego Health La Jolla
        • Kontakt:
        • Ledende efterforsker:
          • Vanessa Tamas, MD
      • Los Angeles, California, Forenede Stater, 90027
        • Ikke rekrutterer endnu
        • Children's Hospital Los Angeles
        • Kontakt:
        • Ledende efterforsker:
          • Ara Festekjian, MD
      • Los Angeles, California, Forenede Stater, 90024
        • Ikke rekrutterer endnu
        • Ronald Reagan UCLA Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Richelle Cooper, MD
      • Palo Alto, California, Forenede Stater, 94304
        • Rekruttering
        • Stanford University Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Alexandra June Gordon, MD
      • Sacramento, California, Forenede Stater, 95817
        • Rekruttering
        • UC Davis Medical Center
        • Ledende efterforsker:
          • Daniel Nishijima, MD
        • Kontakt:
      • San Diego, California, Forenede Stater, 92123
        • Ikke rekrutterer endnu
        • Rady Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Vanessa Tamas, MD
      • San Diego, California, Forenede Stater, 92103
        • Ikke rekrutterer endnu
        • UC San Diego Health Hillcrest Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Vanessa Tamas, MD
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • UCSF Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Debbie Madhok, MD
      • San Francisco, California, Forenede Stater, 94143
        • Rekruttering
        • San Francisco General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Debbie Madhok, MD
      • Torrance, California, Forenede Stater, 90502
        • Ikke rekrutterer endnu
        • Harbor-UCLA Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Juliana Tolles, MD
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06519
        • Rekruttering
        • Yale New Haven Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Charles Wira, MD
    • Delaware
      • Newark, Delaware, Forenede Stater, 19718
        • Rekruttering
        • Christiana Hospital
        • Ledende efterforsker:
          • Jason Nomura, MD
        • Kontakt:
      • Wilmington, Delaware, Forenede Stater, 19803
        • Rekruttering
        • Nemours Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Amy Thompson, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Rekruttering
        • Children's National Medical Center
        • Ledende efterforsker:
          • James Chamberlain, MD
        • Kontakt:
    • Florida
      • Orlando, Florida, Forenede Stater, 32806
        • Rekruttering
        • Orlando Regional Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Dipali Nemade, MD
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30329
        • Rekruttering
        • Arthur M. Blank Hospital
        • Ledende efterforsker:
          • Claudia Morris, MD
        • Kontakt:
      • Atlanta, Georgia, Forenede Stater, 30303
        • Aktiv, ikke rekrutterende
        • Grady Memorial Hospital
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • Rush University Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Michael Gottlieb, MD, MBA
      • Chicago, Illinois, Forenede Stater, 60611
        • Ikke rekrutterer endnu
        • Northwestern Memorial Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Peter Pruitt, MD
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • Comer Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • David Beiser, MD
      • Chicago, Illinois, Forenede Stater, 60612
        • Ikke rekrutterer endnu
        • University of Illinois Hospital
        • Kontakt:
          • Pavitra Kotini-Shah, MD
          • Telefonnummer: 817-703-1723
          • E-mail: pkotini@uic.edu
        • Ledende efterforsker:
          • Pavitra Kotini-Shah, MD
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • David Beiser, MD
    • Indiana
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • Riley Hospital for Children
        • Kontakt:
          • Benjamin Nti, MD
          • Telefonnummer: 317-416-7997
          • E-mail: bnti@iu.edu
        • Ledende efterforsker:
          • Benjamin Nti, MD
      • Indianapolis, Indiana, Forenede Stater, 46202
        • Rekruttering
        • IU Health Methodist Hospital
        • Kontakt:
          • Daniel Udrea, MD
          • Telefonnummer: 317-274-0829
          • E-mail: dudrea@iu.edu
        • Ledende efterforsker:
          • Daniel Udrea, MD
    • Iowa
      • Iowa City, Iowa, Forenede Stater, 52242
        • Rekruttering
        • University of Iowa Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Brett Faine, MD
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 70112
        • Ikke rekrutterer endnu
        • University Medical Center New Orleans
        • Ledende efterforsker:
          • Stephen Lim, MD
        • Kontakt:
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
        • Rekruttering
        • University of Maryland Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jennifer Hopp, MD
      • Baltimore, Maryland, Forenede Stater, 21287
        • Rekruttering
        • Johns Hopkins Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Kathryn Rosenblatt, MD
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Ikke rekrutterer endnu
        • Massachusetts General Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Michael Filbin, MD
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48109
        • Rekruttering
        • University of Michigan University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Mariama Runcie, MD
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Detroit Receiving Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Wazim Mohamed, MD
      • Detroit, Michigan, Forenede Stater, 48202
        • Ikke rekrutterer endnu
        • Henry Ford Hospital
        • Ledende efterforsker:
          • Joseph Miller, MD
        • Kontakt:
      • Detroit, Michigan, Forenede Stater, 48201
        • Rekruttering
        • Sinai-Grace Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Arun Sherma, MD
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • Rekruttering
        • University of Minnesota Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • James Miner, MD
      • Minneapolis, Minnesota, Forenede Stater, 55415
        • Ikke rekrutterer endnu
        • Hennepin County Medical Center
        • Ledende efterforsker:
          • Brian Driver, MD
        • Kontakt:
      • Minneapolis, Minnesota, Forenede Stater, 55414
        • Rekruttering
        • University of Minnesota Masonic Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • James Miner, MD
    • New Jersey
      • Camden, New Jersey, Forenede Stater, 08103
        • Ikke rekrutterer endnu
        • Cooper University Hospital
        • Ledende efterforsker:
          • Christopher Jones, MD
        • Kontakt:
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 87106
        • Ikke rekrutterer endnu
        • University of New Mexico Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Masoom Desai, MD
    • New York
      • Syracuse, New York, Forenede Stater, 13210
        • Ikke rekrutterer endnu
        • SUNY Upstate Medical University
        • Kontakt:
        • Ledende efterforsker:
          • Lindsay Nausin, DO
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Alexander Limkakeng, MD
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45267
        • Rekruttering
        • University of Cincinnati Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Jason McMullan, MD
      • Columbus, Ohio, Forenede Stater, 43205
        • Rekruttering
        • Nationwide Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Aarti Gaglani, MD
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • OSU Wexner Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kirstin Acus, MD
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Oregon Health & Science University Hospital
        • Kontakt:
          • Bory Kea, MD
          • Telefonnummer: 503-494-8083
          • E-mail: kea@ohsu.edu
        • Ledende efterforsker:
          • Bory Kea, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Ikke rekrutterer endnu
        • Hospital of the University of Pennsylvania
        • Kontakt:
        • Ledende efterforsker:
          • John Greenwood, MD
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Ikke rekrutterer endnu
        • Penn Presbyterian Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • John Greenwood, MD
      • Philadelphia, Pennsylvania, Forenede Stater, 19141
        • Rekruttering
        • Jefferson Einstein Philadelphia Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Joseph Herres, DO
      • Philadelphia, Pennsylvania, Forenede Stater, 19111
        • Rekruttering
        • Temple University Hospital Jeanes Campus
        • Kontakt:
        • Ledende efterforsker:
          • Derek Isenberg, MD
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • Rekruttering
        • Temple University Hospital Main Campus
        • Kontakt:
        • Ledende efterforsker:
          • Derek Isenberg, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • UPMC Presbyterian Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Adam Frisch, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15224
        • Rekruttering
        • UPMC Children's Hospital of Pittsburgh
        • Kontakt:
        • Ledende efterforsker:
          • Robert Hickey, MD
      • West Reading, Pennsylvania, Forenede Stater, 19611
        • Rekruttering
        • Reading Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Adam Sigal, MD
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Ikke rekrutterer endnu
        • Children's Medical Center Dallas
        • Kontakt:
        • Ledende efterforsker:
          • Pamela Okada, MD
      • Houston, Texas, Forenede Stater, 77030
        • Rekruttering
        • Memorial Hermann Texas Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kayleigh Fischer, MD
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84108
        • Rekruttering
        • Primary Children's Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Maija Holsti, MD, MPH
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Rekruttering
        • University of Utah Healthcare
        • Kontakt:
        • Ledende efterforsker:
          • Scott Youngquist, MD
    • Virginia
      • Charlottesville, Virginia, Forenede Stater, 22908
        • Rekruttering
        • University of Virginia Medical Center
        • Ledende efterforsker:
          • Thomas Hartka, MD
        • Kontakt:
      • Richmond, Virginia, Forenede Stater, 23298
        • Ikke rekrutterer endnu
        • VCU Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Lisa Merck, MD, MPH, MHA
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • Harborview Medical Center
        • Kontakt:
          • Vasisht Srinivasan, MD
          • Telefonnummer: 585-730-3843
          • E-mail: vasishts@uw.edu
        • Ledende efterforsker:
          • Vasisht Srinivasan, MD
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Children's Hospital of Wisconsin
        • Kontakt:
        • Ledende efterforsker:
          • Keli Coleman, MD
      • Milwaukee, Wisconsin, Forenede Stater, 53226
        • Rekruttering
        • Froedtert Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jamie Jasti, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • The patient was witnessed to have a convulsive seizure for greater than 5-minute duration
  • The patient received an adequate dose of benzodiazepines. The doses may be divided.
  • The last dose of a benzodiazepine was administered 5-30 minutes before study drug administration.
  • Continued or recurring seizures in the Emergency Department.
  • Age 1 years or older
  • Known or estimated weight ≥10 Kg

Exclusion Criteria:

  • Known pregnancy
  • Prisoner
  • Opt-out identification or otherwise known to be previously enrolled in KESETT
  • Treatment with a second line anticonvulsant (FOS, PHT, VPA, LEV, phenobarbital, or other agents defined in the MoP) for this episode of SE
  • Treatment with sedatives with anticonvulsant properties other than benzodiazepines for this episode of SE(propofol, etomidate, ketamine or other agents defined in the MoP)
  • Endotracheal intubation prior to enrollment
  • Acute traumatic brain injury clearly precedes seizures
  • Scalp injury or burn preventing EEG placement
  • Known allergy or other known contraindication to KET or LEV
  • Hypoglycemia < 50 mg/dL
  • Hyperglycemia > 400 mg/dL
  • Cardiac arrest / post-anoxic seizures

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Levetiracetam

Levetiracetam (LEV) (60 mg/Kg)

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Eksperimentel: Levetiracetam + low dose Ketamine

LEV 60 mg/mL + 1 mg/mL KET

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Eksperimentel: Levetiracetam + high dose Ketamine

LEV 60 mg/mL + 3 mg/mL KET increasing up to a weight of 75 kg

The study drug will be produced at the central pharmacy, a GMP facility at the University of California, Davis. Diluted formulations are expected to remain stable for months when stored at room temperature. Expiration dates for study drugs will be determined and adjusted based on ongoing stability testing performed on study drugs prepared at the GMP facility for the study.

All three formulations will be transparent solutions. None of the formulations are reported to consistently cause adverse effects at the infusion site. The method of drug administration, including volume and rate of infusion, is identical for all three drugs. These factors ensure that drug administration will be blinded.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Termination of SE
Tidsramme: From 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication.

Termination of SE from 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication.

Termination of SE is determined by (1) improving consciousness and absence of clinically apparent seizures at 60 minutes or (2) absence of any electrographic status epilepticus (ESE) after 15 minutes in those with EEG monitoring and no improvement in consciousness.

From 15 minutes after starting the study drug infusion, sustained for 60 minutes without using additional anti-seizure medication.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Desirability of response (DOOR) outcome
Tidsramme: 60 minutes after starting the study drug infusion

One secondary outcome will be a desirability of response (DOOR) outcome which is a composite efficacy measure evaluated on a graded scale from 1 to 5 at 60 minutes, as follows:

  • No clinically evident or electrographic seizures after 15 minutes, no rescue drugs, and improving mental status by 60 minutes
  • No clinically evident or electrographic seizures after 15 minutes, not intubated, but not improving mental status at 60 minutes
  • No clinically evident or electrographic seizures after 15 minutes, but intubated or use of additional seizures medications (including medications used for intubation)
  • Any clinically evident seizure or electrographic seizure requiring rescue medicine within the timeframe between 15 and 60 minutes
  • Life-threatening hypotension or cardiac arrhythmia or death within 60 minutes

The Central Adjudication Core will determine the DOOR grade (1-5) based on clinical outcome data provided by the site and EEG data provided by the Central EEG Core.

60 minutes after starting the study drug infusion
Endotracheal intubation
Tidsramme: Within 60 minutes after start of the study drug infusion

Endotracheal intubation within 60 minutes of randomization (start of study drug infusion) and duration

Within 60 minutes after start of the study drug infusion
ICU duration
Tidsramme: Up to 30 days after enrollment

ICU duration during the study period for those that are admitted to the ICU as abstracted from the hospital admission record

Up to 30 days after enrollment
Hospital length-of-stay (LOS)
Tidsramme: Up to 30 days after enrollment

Hospital length-of-stay (LOS) from the ED as abstracted from the hospital admission record

Up to 30 days after enrollment
Late recurrent seizure
Tidsramme: Between 60 minutes and 4 hours after the start of the study drug infusion

Number of participants with late recurrent seizure between 60 minutes and 4 hours after the start of the study drug infusion

Between 60 minutes and 4 hours after the start of the study drug infusion
Time to termination of seizures
Tidsramme: From the start of infusion of study drug to the cessation of electrographic seizure assessed up to 60 minutes from study drug initiation

The interval from the start of infusion of study drug to the cessation of electrographic seizure in those who meet the primary outcome

From the start of infusion of study drug to the cessation of electrographic seizure assessed up to 60 minutes from study drug initiation
Late seizures after requiring an anesthetic
Tidsramme: Between 60 minutes and 24 hours after start of study drug infusion

Number of participants with late seizures after requiring an anesthetic between 60 minutes and 24 hours after start of study drug infusion

Between 60 minutes and 24 hours after start of study drug infusion
All cause mortality
Tidsramme: From the start of study drug infusion to hospital discharge or day 30

All cause mortality to end of study

From the start of study drug infusion to hospital discharge or day 30

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Jaideep Kapur, MD, PhD, University of Virginia

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. marts 2026

Primær færdiggørelse (Anslået)

1. juni 2029

Studieafslutning (Anslået)

1. december 2029

Datoer for studieregistrering

Først indsendt

24. marts 2025

Først indsendt, der opfyldte QC-kriterier

31. marts 2025

Først opslået (Faktiske)

2. april 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. november 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • HSR231657

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data will be stored in Data Archive for the Brain Initiative (DABI) after trial completion. Once submitted to the data repository, we will work with DABI support to ensure that the de-identified KESETT data is available to the public in the DABI search engine where data requests can be submitted.

IPD-delingstidsramme

The timeline of submission of the public use dataset to the repository will comply with all relevant repository guidelines but in general SIREN will submit data to the repository approximately one year after the primary manuscript of the trial is accepted for publication.

IPD-delingsadgangskriterier

Access to the de-identified dataset will be controlled by the data repository. DABI offers two approaches to data access: public or private. The KESETT team plans to make the de-identified data public which means it will be publicly available for downloading to DABI account holders.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .